Maze Therapeutics Inc. (MAZE)
MAZE trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$26.66
-3.75% on the day
Market cap
$1.5B
Small cap
Revenue · 2024
$167.5M
No prior year to compare
Net income · 2024
$52.2M
31.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2024.
Profile
| Field | Value |
|---|---|
| Ticker | MAZE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0001842295 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $167.5M |
| Net income | $52.2M |
| Operating income | $57.6M |
| Net margin | 31.2% |
| Operating margin | 34.4% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $196.8M |
| Total assets | $240.5M |
| P/E (computed) | 28.4× |
| P/S (computed) | 8.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-05-12 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-08-17 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 217 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -0.2% |
| 1 month | +8.2% |
| 3 months | -3.5% |
| Year to date | -36.7% |
| 1 year | -8.3% |
| From 52-week high | -49.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMCR | Immunocore Holdings plc | $27.82 | -4.20% | $1.4B |
| COAG | Hemab Therapeutics Holdings Inc. | $29.80 | -1.94% | $1.4B |
| INBX | Inhibrx Biosciences Inc. | $87.08 | -3.81% | $1.3B |
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| MESO | Mesoblast Limited | $13.89 | -2.63% | $1.8B |
| TSHA | Taysha Gene Therapies Inc. | $3.58 | -13.53% | $1.2B |
| REPL | Replimune Group Inc. | $12.11 | -7.34% | $1.1B |
| VOR | Vor Biopharma Inc. | $19.06 | -3.74% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier